Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Authors

Timothy Voorhees, The Ohio State University Wexner Medical Center, Columbus, OH
Natalie S. Grover, University of North Carolina, Chapel Hill, NC
Eric McLaughlin, The Ohio State University, Columbus, OH
Jorge A. Florindez, University of North Carolina, Chapel Hill, NC
Tamara K. Moyo, Atrium Health / Levine Cancer Institute, Charlotte, NC
Heather Reves, University of Texas Southwestern, Dallas, TX
Nuttavut Sumransub, University of Minnesota, Minneapolis, MN
Saarang Deshpande, University of Pennsylvania, Philadelphia, PA
Ashley Rose, H Lee Mof tt Cancer Center and Research Institute, Tampa, FL
Cassandra Duarte, University of Colorado Cancer Center, Aurora, CO
Muhammad Salman Faisal, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Showkat Hamid, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Suki Subbiah, LSU Health Sciences Center - New OrleansFollow
Sabarish Ayyappan, University of Iowa, Iowa City, IA
Lauren Kelly Shea, University of Alabama at Birmingham, Birmingham, AL
Matthew J. Cortese, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Krish Patel, Swedish Cancer Institute, Seattle, WA
Ajay Major, University of Colorado Cancer Center, Aurora, CO
Hayder Saeed, H Lee Mof tt Cancer Center and Research Institute, Tampa, FL
Jakub Svoboda, University of Pennsylvania, Philadelphia, PA
Sanjal H. Desai, University of Minnesota, Minneapolis, MN
Praveen Ramakrishnan Geethakumari, University of Texas Southwestern, Dallas, TX
Pallawi Torka, Memorial Sloan Kettering Cancer Center, New York, NY
Narendranath Epperla, The Ohio State University Wexner Medical Center, Columbus, OH

Document Type

Conference Proceeding

Publication Date

11-2-2023

Publication Title

Blood

Abstract

65th ASH Annual Meeting, December 9 - 12, 2023, San Diego, CA

First Page

900

Volume

142

Issue

Supplement 1

Comments

ORAL ABSTRACTS 732.ALLOGENEIC TRANSPLANTATION: DISEASE RESPONSE AND COMPARATIVE TREATMENT STUDIES

Recommended Citation

Voorhees, Timothy; Grover, Natalie S.; McLaughlin, Eric; Florindez, Jorge A.; Moyo, Tamara K.; Reves, Heather; Sumransub, Nuttavut; Deshpande, Saarang; Rose, Ashley; Duarte, Cassandra; Faisal, Muhammad Salman; Hamid, Showkat; Subbiah, Suki; Ayyappan, Sabarish; Shea, Lauren Kelly; Cortese, Matthew J.; Patel, Krish; Major, Ajay; Saeed, Hayder; Svoboda, Jakub; Desai, Sanjal H.; Ramakrishnan Geethakumari, Praveen; Torka, Pallawi; and Epperla, Narendranath, "Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers" (2023). School of Medicine Faculty Publications. 3771.
https://digitalscholar.lsuhsc.edu/som_facpubs/3771
10.1182/blood-2023-182385